[康霈*] Phase 3 clinical trial for CBL-514 injection to reduce abdominal subcutaneous fat approved in Canada.
NQ Score
53/100
N1 Content Completeness
10
AI Summary (NQ-processed)
康霈* announced that its second multi-center Phase 3 clinical trial (CBL-0302) for the new drug CBL-514, aimed at reducing abdominal subcutaneous fat, has been approved by Health Canada (HC). The trial will enroll 320 subjects across the US, Canada, and Australia.
AI Analysis
Frequently Asked Questions
- Q: What is a Phase 3 clinical trial?
- A: The final stage of clinical testing to confirm the efficacy and safety of a drug before market approval.